Products

What will AGI do for Brasofensine?

This classification denotes an antiparkinsonian agent with the molecular formula C16H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YP2S94RVH, chemically known as 3-beta-(3,4-dichlorophenyl)-1-alpha-h, 5-alpha-h-tropane-2-alpha-carboxaldehyde (e)-(o-methyloxime). but generally known as brasofensine, which bears US NIH Compound Identifier 9554198. Brasofensine most often comes in base, maleate, and sulfate forms. European Medicines Agency schedules Brasofensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05881MIG. The term BRASOFENSINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). BRASOFENSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brasofensine under HS 29333999 and SITC 51574. As of Q4 2014, BRASOFENSINE remains the US FDA Preferred Term for this commodity. Brasofensine bears US NLM identifiers UMLS ID C0965394 and NCI Concept Code C76391. SMILES: CLC1CC(C2C(C3N(C(C2)CC3)C)/C=N/OC)CCC1CL.